Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27997622 | 0.85 | CHRM3 (0.47) | CHRM3CYP2D6CHRM2CHRM1KCNH2 | |
| SCHEMBL26326653 | 0.82 | CYP2D6 (0.46) | CHRM3CYP2D6CHRM2CHRM1KCNH2 | |
| SCHEMBL2791594 | 0.76 | L3MBTL1 (0.48) | CHRM3CYP2D6CHRM2CHRM1KCNH2 | |
| SCHEMBL4429328 | 0.76 | CHRM2 (0.50) | CHRM3CYP2D6CHRM2CHRM1KCNH2 | |
| SCHEMBL27637612 | 0.73 | KEAP1 (0.46) | CHRM3CYP2D6CHRM2CHRM1KCNH2 | |
| SCHEMBL4278250 | 0.73 | L3MBTL1 (0.45) | CHRM3TSHRTAAR1EPHX2NPC1 | |
| SCHEMBL2238914 | 0.72 | CYP2D6 (0.66) | CHRM3CYP2D6CHRM2CHRM1KCNH2 | |
| SCHEMBL28257085 | 0.72 | CYP2D6 (0.66) | CHRM3CYP2D6CHRM2CHRM1KCNH2 | |
| SCHEMBL60979 | 0.72 | CTSS (0.54) | OPRM1SIGMAR1EPHX2 | |
| SCHEMBL30385299 | 0.72 | FFAR1 (0.35) | CHRM3CYP2D6CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| EP-2454216-A1 | NON-POLAR AND POLAR LEAVING GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| CN-102471176-A | Non-polar and polar leaving groups | BAYER SCHERING PHARMA AG | 2012-05-23 | — | — | CN | disclosed |
| WO-2011006610-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006610-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | PGLS, RABGGTB, LNPEP | CHRM3 2518/4885CYP2D6 844/4885CHRM2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.